The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310511 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Amalia Făgărășan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics III, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mures, Gheor…. Hauptthemen laut MEDLINE: Heart Defects, Congenital, Heart Failure, Cardiovascular Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine, Pharmacy, Science and Technology.
Abstract (Originalsprache)
Galectin-3 (Gal-3) is a novel pro-fibrotic biomarker that can predict both right and left cardiac dysfunction caused by various cardiovascular conditions. Its expression seems to be progressively altered with evolving cardiac remodeling processes, even before the onset of heart failure. Hence, Gal-3 has been found to be an individual predictor of acute and chronic heart failure or to serve as part of an integrated biomarker panel that can foresee adverse cardiac outcomes. In congenital heart disease (CHD), Gal-3 correlates with cardiac mortality and complications in both children and adults and is proposed as a therapeutic target in order to reverse the activation of pro-fibrosis pathways that lead to heart failure. Positive associations between serum Gal-3 levels, post-operatory hospitalization rates, complications and ventricular dysfunction have also been reported within studies conducted on patients with CHD who underwent corrective surgery. Thus, this review tried to address the potential utility of Gal-3 in patients with CHD and particularly in those who undergo corrective surgery. The heterogeneity of the literature data and the lack of validation of the results obtained by the current studies on larger cohorts cannot be neglected, though. Further longitudinal research is required to establish how Gal-3 can relate to long-term outcomes in pediatric CHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics III, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mures, Gheorghe Marinescu Street no 38, 540136 Târgu Mures, Romania.
- Department of Pediatrics III, Faculty of Medicine in English, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mures, Gheorghe Marinescu Street no 38, 540136 Târgu Mures, Romania.
- Department of Medical Genetics, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mures, Gheorghe Marinescu Street no 38, 540136 Târgu Mures, Romania.
- Genetics Department, Center for Advanced Medical and Pharmaceutical Research, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, Gheorghe Marinescu Street no 38, 540136 Târgu Mu…
ORCID-Profile: Amalia Făgărășan, Maria Săsăran, Claudia Bănescu
Förderung
- University of Medicine, Pharmacy, Science and Technology
Zitieren
APA
Făgărășan, A., Săsăran, M., Gozar, L., Crauciuc, A., & Bănescu, C. (2023). The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310511
Vancouver
Făgărășan A, Săsăran M, Gozar L, Crauciuc A, Bănescu C. The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310511
BibTeX
@article{Fgran2023,
author = {Făgărășan, Amalia and Săsăran, Maria and Gozar, Liliana and Crauciuc, Andrei and Bănescu, Claudia},
title = {The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310511}
}
EUVIMED